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Introduction: Polycystic ovarian syndrome (PCOS) is a leading cause of female
subfertility worldwide, however due to the heterogeneity of the disorder, the criteria for
diagnosis remains subject to conjecture. In the present study, we evaluate the utility
of serum Anti-Müllerian hormone (AMH) in the diagnosis of menstrual disturbance due
to PCOS.
Method: Menstrual cycle length, serum AMH, gonadotropin and sex-hormone levels,
total antral follicle count (AFC), body mass index (BMI) and ovarian morphology on
ultrasound were analyzed in a cohort of 187 non-obese women, aged 18–35 years,
screened for participation in a clinical trial of fertility treatment between 2013 and 2016
at a tertiary reproductive endocrine center.
Results: Serum AMHwas higher in women with menstrual disturbance when compared
to those with regular cycles (65.6 vs. 34.8 pmol/L; P < 0.0001). The odds of menstrual
disturbance was increased 28.5-fold (95%CI 3.6–227.3) in womenwith serum AMH>60
pmol/L, in comparison to those with an AMH < 15 pmol/L. AMH better discriminated
women with menstrual disturbance (area under ROC 0.77) from those with regular
menstrual cycles than AFC (area under ROC 0.67), however the combination of the two
markers increased discrimination than either measure alone (0.83; 95% CI 0.77–0.89).
Serum AMH was higher in women with all three cardinal features of PCOS (menstrual
disturbance, hyperandrogenism, polycystic ovarian morphology) when compared to
women with none of these features (65.6 vs. 14.6 pmol/L; P < 0.0001). The odds of
menstrual disturbance were increased by 10.7-fold (95% CI 2.4–47.1) in women with
bilateral polycystic morphology ovaries than those with normal ovarian morphology. BMI
was a stronger predictor of free androgen index (FAI) than either AMH or AFC.
Conclusion: Serum AMH could serve as a useful biomarker to indicate the risk of
menstrual disturbance due to PCOS. Women with higher AMH levels had increased rates
of menstrual disturbance and an increased number of features of PCOS.
Keywords: polycystic ovarian syndrome (PCOS), antral follicle count (AFC), Anti-Müllerian Hormone (AMH),
amenorrhea, oligomenorrhea, hyperandrogenism
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INTRODUCTION
Polycystic Ovarian Syndrome (PCOS) is a leading cause of
anovulatory infertility, which affects up to 21% of women of
reproductive age (1, 2). PCOS is characterized by a spectrum of
signs and symptoms encompassing androgen excess, ovulatory
disruption, polycystic ovarian (PCO) morphology and metabolic
abnormalities, however no single feature is requisite for the
diagnosis (1–3). Therefore, the diagnosis of PCOS can be
challenged by the heterogeneity and complexity of its phenotypic
presentation (4, 5).
The Rotterdam criteria is most widely-used for the diagnosis
of PCOS, requiring the presence of two or more of the
following features: oligo/amenorrhea, clinical or biochemical
hyperandrogenism, and PCO morphology on ultrasound (6).
More recently, international guidelines have updated the criteria
for diagnosis of PCOS (2). A major feature of the diagnosis of
PCOS is the presence of PCO morphology on ultrasound, which
describes the typical peripheral pattern of follicular distribution
in the ovary around a central stroma (7, 8). However, due to
the subjective interpretation of this feature, PCO morphology is
more commonly defined by follicle number per ovary (FNPO) (1,
2). Whereas, the Rotterdam criteria defined PCOmorphology by
the presence of at least 12 FNPO, due to advances in ultrasound
resolution these criteria have been revised to be at least 20 FNPO
in the updated guidelines (2).
AMH is a member of the transforming growth factor-β
superfamily that is produced by growing ovarian antral follicles
(1, 2, 9). Serum Anti-Müllerian hormone (AMH) correlates
with the total number of antral follicles over both ovaries, and
therefore has been proposed as a biomarker for PCOS diagnosis
(9, 10). AMH has the advantage of being non-invasive and is
relatively stable across the menstrual cycle, whereas AFC and
ovarian morphology are best assessed during the follicular phase
(9). However, due to the variability in levels using older less
reliable assays (11) and the lack of an international standard
(9, 12), AMH has yet to be adopted as part of the diagnostic
criteria for PCOS (2).
More recently, an emerging hypothesis proposes that AMH
may play a key role in the pathogenesis of PCOS as an
endocrine signal rather than being merely a marker of ovarian
follicle count (13, 14). A subset of gonadotropin releasing
hormone (GnRH) neurons express the AMH receptor, and
administration of AMH stimulates GnRH neuronal firing
(15). Pituitary gonadotropes are sensitive to alterations in
GnRH pulsatility, such that increased GnRH pulsatility is
associated with LH-predominant gonadotropin secretion, which
is a characteristic, albeit not universal, feature of PCOS (16,
17). Women with PCOS have higher levels of AMH than
matched controls (18, 19). AMH levels fall with increasing age,
which is concurrent with an improvement in some clinical
features of PCOS (9, 20). For example, women with PCOS
who are anovulatory may normalize their menstrual cycles
with increased age (21). Indeed, cycle length shortens with
increasing age prior to the climacteric even in women without
PCOS, corresponding to a fall in ovarian reserve markers
(9, 22).
In the present study, we analyzed serum AMH and ovarian
morphology on ultrasound, in a cohort of 187 non-obese young
women screened for participation in a clinical trial of fertility
treatment between 2013 and 2016 to evaluate the utility of serum
AMH in the prediction of menstrual disturbance due to PCOS.
MATERIALS AND METHODS
Study Participants
Data was obtained from women screened for participation
in a clinical trial of the novel trigger kisspeptin during
IVF treatment conducted between 2013 and 2016 (23–25).
The trial was registered on the National Institutes of Health
Clinical Trials database (NCT01667406) and was approved
by the Hammersmith and Queen Charlotte’s Research Ethics
Committee, London, UK (reference: 10/H0707/2). All recruited
participants provided written informed consent prior to
inclusion in the study with the Declaration of Helsinki. Inclusion
criteria for the trial were women aged 18–35 years with both
ovaries intact, BMI 18–30 kg/m2, serum AMH more than
10 pmol/L. Women with moderate/severe endometriosis or
poor response to or >2 previous cycles of IVF treatment
were excluded.
Clinical, biochemical and sonographic features of PCOS were
analyzed to determine the relationship between serum AMH
level, menstrual disturbance, total AFC on ultrasound, bodymass
index (BMI), serum gonadotropin levels, and androgen levels.
During screening, women were clinically assessed by experienced
physicians and provided a detailed menstrual cycle history,
including number of menses per year, age of menarche, duration
of menstrual cycle, previous use of hormonal contraceptive,
as well as smoking history, medical conditions, medication
use and duration of infertility. Oligomenorrhea was defined
as menstrual cycle intervals ≥35 days (or 4–8 periods per
year), whereas amenorrhea was defined as ≤3 menses per year.
Biochemical evaluation included serum luteinizing hormone,
LH; follicle stimulating hormone, FSH, testosterone, estradiol,
and progesterone, sex hormone–binding globulin (SHBG),
serum AMH measurements and free androgen index (FAI)
(total testosterone in nmol/L × 100/SHBG in nmol/L). Total
antral follicle count (AFC) and serum AMH were measured
during the follicular phase (days 1–5) of the menstrual cycle.
A transvaginal pelvic ultrasound was performed by one of
three specialist sonographers using a 7.5 MHz transvaginal
probe (Toshiba Xario Prime, Crawley, UK). The number of
antral follicles (2–10mm) per ovary (FNPO), was measured
in the maximum plane section of both ovaries. In addition
to classification by FNPO, morphological appearance was also
classified as being polycystic ovarian (PCO) morphology if
follicles were peripherally distributed around a central stroma
or multicystic ovarian (MCO) morphology if ovaries had an
increased number of follicles that were uniformly distributed.
Assays
Serum LH, FSH, oestradiol, and testosterone were measured
using automated chemiluminescent immunoassays (Abbott
Diagnostics, Maidenhead, UK). Interassay coefficients of
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variations were as follow: LH 3.4%, FSH 3.5%; oestradiol, 3.4%;
testosterone 3.6%. Limits of detectability for each assay are
as follows LH 0.07 mIU/mL; FSH 0.05 mIU/mL; oestradiol
70 pmol/L (19 pg/mL); testosterone 0.08 nmol/L. AMH was
measured using an enzyme linked immunosorbent assay
(Beckman Coulter Inc, Brea, CA, USA). The reference range was
2.2–48.5 pmol/L (0.3–6.8 ng/mL) with a lower limit of detection
of 0.6 pmol/l (0.08 ng/mL). The upper limit of detection for
the AMH assay was 68.9 pmol/L. Testosterone is measured
first-line by immunoassay and all elevated female testosterone
results>2.0 nmol/L are reflexed for confirmation by LC-MS/MS.
The interassay coefficient of variation was 4.6%; the intraassay
coefficient of variation was 4.0%.
Statistical Analysis
Analyses were conducted using Graphpad Prism version 7.0
and Stata Version 14.0 statistical software. Relative predictive
performance analysis by random forest analysis and ROC
curve analysis was performed in R version 3.5.1. Continuous
variables that were parametrically distributed were reported by
mean ± standard deviation (SD), whereas skewed continuous
variables were summarized using median ± interquartile range
(IQR). Parametrically distributed variables were compared using
unpaired student’s t-test (two groups) or one-way ANOVA
(multiple groups). Non-parametrically distributed variables were
compared using Kruskal-Wallis test or Mann Whitney as
appropriate. Categorical data were compared using X2 or
logistic regression.
RESULTS
Baseline Characteristics
Of 207 women who were screened for the parent study, 187 for
whom data was available were included in the present study.
Baseline characteristics of the 187 included participants are
summarized in Table 1. Oligo/amenorrhea was present in one
third of women; women with oligo/amenorrhea had higher BMI
(25.0 vs. 23.3 kg/m2), AMH (65.6 vs. 34.8 pmol/L), AFC (38 vs.
29), and FAI (3.0 vs. 2.1%) (Table 1).
Clinical Features of PCOS and AMH/AFC
Total AFC on ultrasound was increased by category of serum
AMH (Figure 1A). Oligo/amenorrhea was more frequent by
increasing category of AMH (Figure 1B), or AFC (Figure 1C).
The odds of oligo/amenorrhea were increased 28.5-fold (95% CI
3.6–227.3) in women with AMH >60 pmol/l, when compared to
those with AMH < 15 pmol/L (Figure 1B). There was a trend
toward higher AMH levels in patients with longer self-reported
menstrual cycle length even in eumenorrheic women with cycle
lengths <35 days (Figure 1D).
Serum AMH was higher in patients with more
features consistent with PCOS (menstrual disturbance,
hyperandrogenism, PCOM by Rotterdam criteria) (Figure 2A).
Women with all three features had a significantly higher median
serum AMH compared to those with none of these features
(65.6 vs. 14.6 pmol/L; P < 0.0001). Similarly, median AFC
(Figure 2B), free androgen index (FAI; Figure 2C) and BMI
TABLE 1 | Baseline characteristics of patients with oligo/amenorrhea and women
with regular cycles.
Eumenorrhea Oligo/
Amenorrhea
Total P-value
No (%) 126 (67.4%) 61 (32.7%) 187 (100%)
Ethnicity (%)
Asian 33 (26.2) 20 (32.8) 53 (28.3)
Black 7 (5.55) 3 (4.92) 10 (5.35)
White 75 (59.6) 33 (54.1) 108 (57.8)
Other 12 (9.52) 4 (6.56) 16 (8.56)
Age (years) 31.0
(29.0, 33.0)
30.0
(28.0, 32.9)
31.0
(28.4, 33.0)
0.34
Age at menarche (years) 12.2
(11.5, 13.2)
13.0
(11.3, 13.0)
12.4
(11.3, 14.0)
0.28
BMI (kg/m2) 23.3
(21.7, 23.7)
25.0
(22.3, 28.4)
23.7
(21.8, 26.9)
0.02
Total antral follicle count 29 (24,37) 38 (28, 50) 30 (25,44) <0.001
Ovarian volume (ml) 6.0
(2.5, 10.2)
6.9
(3.2, 12)
8.3
(6.1, 10.5)
0.01
Anti-Mullerian hormone
(pmol/L)
34.6
(20.7, 52.2)
65.8
(45.8, 69.0)
45.0
(25.7, 69)
<0.001
Androstenedione (nmol/L)* 4.8
(3.8, 6.5)
4.0
(3.2, 5.5)
4.4
(3.6, 6.2)
0.06
Testosterone (nmol/L) 1.2
(0.9, 1.6)
1.4
(1.1, 1.8)
1.3
(1, 1.6)
0.03
Dehydroepiandrostenedione
(DHEA) (µmol/L)**
5.4
(4.2, 9.4)
5.5
(4.4, 6.9)
5.5
(4.3, 7.0)
0.94
Free androgen index (FAI) 2.1%
(1.5%, 4.0%)
3.0%
(1.9%, 5.1%)
2.5%
(1.6%, 4.5%)
0.02
Median and interquartile range (IQR) are presented. Groups were compared by Mann-
Whitney U test.
*Data was available for 35 eumenorrheic women and 40 oligo/amenorrheic women.
**Data was available for 29 eumenorrheic women and 35 oligo/amenorrheic women.
(Figure 2D) were also higher in women with all three features
consistent with PCOS compared to women with none of these
features. Results were similar when PCO morphology was
categorized as per the new international PCOS guidelines
(Supplementary Figure 1) (2).
Follicular phase serum gonadotropin levels were progressively
more LH-predominant (consistent with increased GnRH
pulsatility) by increasing categories of serum AMH (Figure 3A),
or AFC (Figure 3B). Oligo/amenorrhea was more frequent in
women with more LH-predominant gonadotropin secretion
(Figure 3C), or higher FAI levels (Figure 3D). The odds of
oligo/amenorrhea were increased by 13.9-fold (95% CI 1.6–121)
in women with serum LH-FSH exceeding 7 iU/L when compared
with those with a value <1 iU/L (P = 0.017) (Figure 3C). The
odds of oligo/amenorrhea for women with an FAI>4.5 was
increased by 2.9-fold (95% CI 1.0–16.8) compared to those with
an FAI < 1.5 (P = 0.039) (Figure 3D).
Oligo/Amenorrhea
Median serum AMH was significantly higher in women with
oligo/amenorrhea when compared to women with regular
menstrual cycles (65.6 vs. 34.8 pmol/L; P < 0.0001) (Figure 4A).
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FIGURE 1 | (A) Scattergram (median ± IQR) of serum anti-Mullerian hormone, AMH (pmol/L), by total antral follicle count (AFC) across both ovaries. Groups were
compared by Kruskal Wallis test with post-hoc Dunn’s multiple comparison test. AFC was significantly higher by category of serum AMH. **P < 0.01, ***P < 0.001,
****P < 0.0001. (B) Frequency of oligomenorrhea was increased by category of serum AMH (pmol/L) when compared by univariate logistic regression (P < 0.0001).
The sample size in each AMH category is as follows: <15 pmol/L (n = 20); 15–30 pmol/L (n = 39), 30–44.9 pmol/L (n = 33), 45–59.9 (n = 33), >60 pmol/L (n = 60).
The odds of oligomenorrhea was increased 2.2-fold (95% CI 0.2–20.8) in those with AMH 15–30 pmol/L; 6.1-fold (95% CI 0.70–52.9) in those with AMH 30–44.9
pmol/L; 9.5-fold (95% CI 1.1–80.5) in those with AMH 45–59.9 pmol/L; and 28.5-fold (95% CI 3.6–227.3) in those with AMH >60 pmol/L, compared to those with
AMH < 15 pmol/L. (C) Frequency of oligomenorrhea was increased by categories of AFC when compared by univariate logistic regression (P < 0.0001). The number
of patients in each category is as follows: AFC < 20 (n = 26); 20–35 (n = 91); 36–60 (n = 55), >60 (n = 15). The odds of oligomenorrhea was increased 9.5-fold
(95% CI 1.2–73.6) in those with AFC 20–35; 22.4-fold (95% CI 2.8–177.2) in those with AFC 36–60; and 37.5-fold (95% CI 3.6–332) in those with AFC >60 when
compared to those with AFC < 20. (D) Scattergram (median ± IQR) of serum AMH (pmol/L) by average menstrual cycle lengths. Groups were compared by the
Kruskal Wallis test with post-hoc Dunn’s multiple comparisons test. Women with average menstrual cycle length of ≥35 days have higher AMH levels compared to
those with menstrual cycle length of ≤27 days (P < 0.0001) or those with menstrual cycle length of 28–30 days. ****P < 0.0001.
Total AFC was also higher in women with oligo/amenorrhea (38
vs. 29, P < 0.0001) (Figure 4B). Serum AMH (area under ROC
0.77) better discriminated women with oligo/amenorrhea from
those with regular menstrual cycles than AFC (area under ROC
0.67), however the combination of the two performed better than
either marker alone (area under ROC 0.83; 95% CI 0.77–0.89)
(Figure 4C). The odds of oligo/amenorrhea were increased by
6.7-fold (95% CI 2.5–19.9) in those with an AMH per antral
follicle of >2 pmol/L when compared with those with an AMH
per antral follicle of <1 pmol/L (P < 0.0001) (Figure 4D).
PCOS DIAGNOSIS
In the present cohort, 97 of 182 (53.5%) patients had PCOS
by the Rotterdam criteria and 75 of 182 (41.2%) by the new
international criteria (2). Menstrual disturbance was present
in none of the women without PCOS and 60% of women
with PCOS by Rotterdam criteria. Whereas, 8.4% of woman
without PCOS and 65% of women with PCOS by the new
international criteria had menstrual disturbance. Women with
either eumenorrheic or oligo/amenorrheic PCOS had higher
serum AMH levels than women without PCOS diagnosed
by either Rotterdam criteria or by the new International
criteria (Supplementary Table 1). Whilst AMH was higher in
women with oligo/amenorrheic PCOS than in women with
eumenorrheic PCOS (P < 0.009), AFC did not significantly
differ (P>0.3) (Supplementary Table 1). Presence of one PCO
morphology ovary defined by Rotterdam criteria had 100%
sensitivity and 43.7% specificity to diagnose PCOS, as compared
with 47.6% sensitivity and 71.0% specificity if PCO was defined
by the international criteria.
The strongest predictors for the diagnosis of PCOS
were serum AMH and serum testosterone. Despite
hyperandrogenemia forming part of the diagnostic criteria
of PCOS, its diagnostic performance in identifying PCOS
diagnosed by standard means was less than that of AMH.
The auROC for testosterone to identify PCOS was 0.70, and
auROC for Free Androgen Index (FAI) was 0.71 by Rotterdam
criteria. The equivalent figures for auROC for testosterone
and FAI if PCOS was diagnosed by the new international
criteria was 0.71 and 0.72, respectively. A combination of serum
AMH and testosterone identifies the diagnosis of PCOS using
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FIGURE 2 | (A) Scattergram (median ± IQR) of serum AMH (pmol/L) by the number of features of PCOS (Rotterdam criteria). Groups were compared by the Kruskal
Wallis test with post-hoc Dunn’s multiple comparison test. Serum AMH was increased by the number of features of PCOS. *P < 0.05, **P < 0.01, ***P < 0.001, ****P
< 0.0001. (B) Scattergram (median ± IQR) of total antral follicle count (AFC) in women by the number of features of PCOS (Rotterdam criteria). Groups were
compared by Kruskal Wallis test with post-hoc Dunn’s multiple comparison test. AFC was increased by the number of features of PCOS. *P < 0.05, **P < 0.01, ***P
< 0.001, ****P < 0.0001. (C) Scattergram (median ± IQR) of Free Androgen Index, FAI, in women by the number of features of PCOS (Rotterdam criteria). Groups
were compared by the Kruskal Wallis test with post-hoc Dunn’s multiple comparison test. FAI was increased by the number of features of PCOS. **P < 0.01, ***P <
0.001. (D) Scattergram (median ± IQR) of Body Mass Index, BMI (kg/m2 ), in women by the number of features of PCOS (Rotterdam criteria). Groups were compared
by the Kruskal Wallis test with post-hoc Dunn’s multiple comparison test. BMI was increased by the number of features of PCOS. **P < 0.01, ***P < 0.001.
the Rotterdam criteria with an area under the ROC of 0.79
(95% CI 0.69–0.86), and of the diagnosis of PCOS by the new
international criteria with an area under the ROC of 0.77 (95%
CI 0.67–0.85).
Ovarian Morphology on Ultrasound
Whilst AMH (Supplementary Figure 2A) and FAI
(Supplementary Figure 2C) were not significantly different
by categories of ovarian morphology, total AFC was higher
in women with two ovaries having PCO morphology
by Rotterdam criteria (Supplementary Figure 2B). The
frequency of oligo/amenorrhea was highest in women
with two ovaries demonstrating PCO morphology at 47%
(Supplementary Figure 2D). The odds of oligo/amenorrhea
were increased by 10.7-fold in womenwith two PCOmorphology
ovaries compared to women with normal ovarian morphology
(Supplementary Figure 2D).
The distinction between PCO and MCO lies in the
amount and distribution of non-follicular stromal tissue
(26). Ovarian volume correlates with antral follicle count
(Supplementary Figure 3A). Thus, ovarian volume is higher
in PCO morphology ovaries than normal morphology
ovaries (Supplementary Figure 3B). Therefore, we assessed
“ovarian volume per follicle” as an objective surrogate
measure of the amount of non-follicular stromal tissue.
Ovarian volume per follicle was higher in normal
morphology ovaries than MCO ovaries, or PCO ovaries
(Supplementary Figure 3C). Women with bilateral
polycystic morphology ovaries had lower ovarian volume
per follicle than those with normal morphology ovaries
(Supplementary Figure 3D). Women with greater AMH
levels (Supplementary Figure 3E) had lower ovarian volume
per follicle and this was associated with an increased risk of
oligo/amenorrhea (Supplementary Figure 3F).
Relationship Between Body Weight and FAI
Serum testosterone was increased (Figure 5A), SHBG level
decreased (Figure 5B) and FAI increased (Figure 5C) by
category of BMI in non-obese women. There was a trend
toward an increase in FAI with BMI even when stratified by
AFC (Figure 5D). Body fat mass was the strongest predictor
of serum testosterone (P < 0.05) followed by AMH and
AFC. Using all three to predict log-adjusted testosterone has
an r2 of 15%.
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FIGURE 3 | (A) Bar graph (Median ± IQR) of serum LH-FSH (iU/L) by categories of serum AMH (pmol/L) in women presenting with oligo/amenorrhea, or
eumenorrheic women in the follicular phase of the menstrual cycle (days 1–8). Groups were compared by the Kruskal Wallis test with post-hoc Dunn’s multiple
comparison test. Gonadotropin secretion was more LH-predominant with increasing category of AMH. *P < 0.05, ***P < 0.001. (B) Bar graph (median ± IQR) of
serum LH-FSH (iU/L) by categories of AFC in women presenting with oligo/amenorrhea or eumenorrheic women in the follicular phase of the menstrual cycle (days
1–8). Groups were compared by the Kruskal Wallis test with post-hoc Dunn’s multiple comparison test. Gonadotropin secretion was more LH-predominant with
increasing category of AFC. *P < 0.05, **P < 0.01. (C) Frequency of oligomenorrhea was higher by increasing categories of serum LH-FSH (iU/L) when compared by
univariate logistic regression (P = 0.003). The number of women in each category were as follows: serum LH-FSH < 1 iU/L (n = 29); 1–7 iU/L (n = 44), >7 iU/L (n =
14). The odds of oligomenorrhea was increased by 3.6-fold (95% CI 1.3–10.0) in those with serum LH-FSH 1–7 iU/L and by 13.9-fold (95% CI 1.6–121) in those with
serum LH-FSH >7 iU/L compared to those with serum LH-FSH < 1 iU/L. (D) The frequency of oligomenorrhea were higher by category of Free Androgen Index (FAI).
The number of women in each categories of FAI were as follows: FAI < 1.5 (n = 34); 1.5–4.5 (n = 94); >4.5 (n = 44). When compared by univariate logistic
regression, the odds of oligomenorrhea was increased 2.9-fold (95% CI 1.0–16.8) in those with FAI > 4.5 compared to those with FAI < 1.5 (P = 0.039).
DISCUSSION
PCOS affects up to a fifth of women of reproductive age
and is the commonest cause of anovulatory subfertility (2).
Diagnostic criteria for PCOS inevitably transform continuous
variables into binary data to facilitate reproducible identification
of PCOS. However, many features of PCOS span a spectrum
encompassing both health and disease. Furthermore, women
with very high AFC are considered no differently to those
meeting a threshold value of FNPO to denote PCO morphology.
Data from the present study suggests that women with
greater increases in ovarian reserve markers, such as AMH
or AFC, have an increased risk of menstrual disturbance
beyond those with more modest elevations. Additionally,
women with more features of PCOS had higher AMH
levels than those with fewer features. Moreover, women with
higher AMH levels had more LH-predominant gonadotropin
secretion consistent with increased GnRH pulsatility. AMH
more reliably identified women with PCOS than AFC, but
the combination of both ovarian reserve markers better
identified PCOS than either marker alone. Overall, our
data suggests that AMH has potential as a biomarker for
diagnosis of PCOS, outperforming AFC, and greater elevations
in AMH were associated with a more certain diagnosis
of PCOS.
AMH is secreted by growing antral follicles and thus can
be regarded as a surrogate marker of antral follicle count.
Locally, AMH plays a paracrine role to inhibit FSH-induced
aromatase activity in granulosa cells and aids in the emergence
of a dominant follicle (27). However, there is increasing interest
in a further putative role for AMH in the pathogenesis of
PCOS, acting as an endocrine signal to directly increase GnRH
pulsatility (15, 17). Indeed, our data demonstrates that follicular
phase gonadotropin levels became more LH-predominant,
commensurate with an increase in GnRH pulsatility, in those
with greater AMH values. Notably, women with more LH-
predominant gonadotropin secretion also had increased rates of
menstrual disturbance. Pulse frequency is increased in women
with PCOS (healthy controls 16.5, PCOS 22.8 pulse per 24 h),
however LH pulse amplitude is reduced in obese (BMI >30
kg/m2) women with PCOS, which needs to be considered when
interpreting the LH to FSH ratio (28). In our cohort, all women
had a BMI < 30 kg/m2 and thus gonadotropin secretion was less
affected by obesity.
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FIGURE 4 | (A) Scattergram (median ± IQR) of serum AMH (pmol/L) in eumenorrheic women and in women with oligo/amenorrhea. Groups were compared by the
Mann-Whitney U test. Women with oligomenorrhea/amenorrhea had statistically significant higher serum AMH. ****P < 0.0001. (B) Scattergram (median ± IQR) of
total AFC in eumenorrheic women and in women with oligo/amenorrhea. Groups were compared by the Mann-Whitney test. Women with oligo/amenorrhea had
higher AFC than eumenorrheic women. **P < 0.01. (C) Receiver Operating Characteristic (ROC) curves for the prediction of oligo/amenorrhea using serum AMH
(pmol/L) and AFC. (D) Frequency of oligomenorrhea increased with category of AMH per antral follicle (serum AMH value divided by total antral follicle count) when
compared by univariate logistic regression (P = 0.001). The odds of oligomenorrhea was increased by 1.9-fold (95% CI 0.9–4.1) in those with AMH per antral follicle
1–2 pmol/L, and 6.7-fold (95% CI 2.5–19.9) in those with AMH per antral follicle >2 pmol/L compared to those with an AMH per antral follicle <1 pmol/L.
In the present study, the risk of oligo/amenorrhea was
gradually increased with serum AMH level rather than the risk
being defined by a single threshold. Moreover, there was a trend
toward increased cycle length with AMH level in eumenorrheic
women in keeping with a recent report (22). Furthermore, whilst
AMH levels correlated with AFC, serum AMH better predicted
the risk of oligo/amenorrhea than AFC. Accordingly, women
with amenorrheic PCOS have been reported to have higher AMH
levels than those with oligomenorrheic PCOS, and in turn than
eumenorrheic PCOS, and healthy controls (29). Interestingly,
in our data the combination of AMH and AFC appeared to
improve the prediction of oligo/amenorrhea when compared to
each measure alone. Indeed, women with higher AMH per antral
follicle had increased odds of oligo/amenorrhea than those with
lower values.
Another key feature of PCOS is the presence of
hyperandrogenism. Women with elevated BMI have an
increased prevalence of PCOS, and thus could also have
increased levels of androgens. The prevalence of PCOS is
increased by obesity, although not dramatically (BMI < 19
kg/m2 8%, BMI 19–30 kg/m2 9.9%, BMI 30–35 kg/m2 5.2%, BMI
> 35 kg/m2 11.5–12.4%) (30). However, our data suggested that
FAI was more strongly predicted by BMI than by AMH, although
women with both increased BMI and high follicle counts were
most at risk of biochemical hyperandrogenism (Figure 5D).
In keeping with BMI being the strongest predisposing factor,
androgen levels have been reported to be higher in women
with PCOS with a BMI >25 kg/m2 than those with lower BMI’s
(31, 32). Similarly, FAI, but not total testosterone, were reported
to correlate with BMI, both in women with and without PCOS
(31, 32). Correspondingly, Penttila et al. have observed that FAI
was increased by BMI in healthy controls and in women with
PCOS, whether hirsuitism was present or not (32, 33).
Whilst androgen production in PCOS is predominantly of
ovarian origin, driven by insulin resistance and exacerbated
by BMI, recent data has suggested that other organs, such
as adipose tissue can also be a site of androgen production.
The androgenic enzyme aldoketoreductase type 3 (AKR1C3) is
expressed in subcutaneous adipose tissue and is stimulated by
insulin to contribute to hyperandrogenism in obese women (34).
Additionally, Deng and colleagues have observed that adrenal-
derived androgens may be of particular relevance in lean women
with PCOS (35).
Due to the subjective nature of describing PCO morphology
based on the appearance of peripherally located follicles around
a central stroma (26), PCO morphology is more commonly
defined by follicle number per ovary regardless of distribution
(2). Multicystic ovarian (MCO) morphology, in which follicle
number is increased without the typical distribution, may
be associated with hypothalamic amenorrhea, or during
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FIGURE 5 | (A) Bar graph (median ± IQR) of serum testosterone (nmol/L) by categories of BMI (kg/m2). Groups were compared by the Kruskal-Wallis test with
post-hoc Dunn’s multiple comparison test. Serum testosterone was increased by category of BMI. ***P < 0.001. (B) Bar graph (median ± IQR) of serum sex hormone
binding globulin, SHBG (nmol/L) by categories of BMI (kg/m2). Groups were compared by the Kruskal-Wallis test with post-hoc Dunn’s multiple comparison test.
SHBG was reduced in women with higher BMI. *P < 0.05, **P < 0.01, ****P < 0.0001. (C) Bar graph (median ± IQR) of Free Androgen Index, FAI by categories of
BMI (kg/m2). Groups were compared by the Kruskal-Wallis test with post-hoc Dunn’s multiple comparison test. FAI was increased by BMI category. *P < 0.05, **P <
0.01, ****P < 0.0001. (D) Bar graph (median ± IQR) of FAI by categories of BMI (kg/m2) stratified by AFC. Median and range is presented. FAI in those with AFC 23
are shown in blue, 24–40 in orange and ≥41 in red.
adolescence, reflecting hypothalamo-pituitary dysfunction (36–
38). In our data, women with PCO morphology in both ovaries
had higher AMH, AFC, and rates of menstrual disturbance
than in women with at least one ovary with normal ovarian
morphology. We strived to objectively quantify the distinction
between MCO and PCO morphology by assessing “ovarian
volume per antral follicle” (Supplementary Figure 3). Thus, our
data is in keeping with the concept that MCO morphology may
represent a milder phenotype than those with PCO morphology
(39), but definition of ovarian morphology by appearance did
not appear to be superior to definition by FNPO.
A number of studies have evaluated the ability of an AMH
threshold value to diagnose PCOS. AMH levels were higher
in women with PCOS and polycystic ovarian morphology (9.3
mcg/L) than those without PCO morphology alone (6.4 mcg/L),
or healthy controls (2.1 mcg/L) (19). AMH was 9.1 mcg/L in
women with PCOS and 2.5 mcg/L in controls (40). Similarly,
AMH was 5.7 ng/ml in healthy controls, 9.3 ng/ml in women
with PCOS and 9.9 ng/ml in women with all three main features
of PCOS (41). Using cluster analysis, age was found to be an
important modifying variable for AMH to differentiate PCOS
from PCO morphology and from healthy women (21). A meta-
analysis determined that an AMH of 4.7 ng/ml had a 79.4%
sensitivity and 82.8% specificity to identify PCOS (auROC 0.87)
(42). In summary, a number of studies suggest that AMH
could represent a useful marker for the diagnosis of PCOS,
however challenges to the use of AMH to diagnose PCOS are
usefully summarized in Teede et al. (43). Outstanding areas of
research include the need for data using standardized optimal
assays, to associate thresholds with clinical features of PCOS,
and to stratify reference ranges by age (43). Pigny et al. (11)
compared the performance of five commercial AMH assays in
the diagnosis of PCOS and found that whilst the assays offered
similar performance, newer automated assays reported 23–30%
lower values than manual assays (11). Our data is in keeping with
the view that women with PCOS have a spectrum of phenotypic
presentation that can be altered by baseline variables, such as
age or BMI e.g., women with PCOS are less likely to have
oligo/amenorrhea in older years (44). Thus, the construct of risk-
models using continuous variables to quantify the likelihood of
PCOS from an unselected population would be of value, although
this remains challenged by the lack of an objective gold standard
test to diagnose PCOS.
Strengths of our data include that women were routinely
screened for features of PCOS by a specialist unit with experience
in the accurate assessment of AFC and ovarian morphology with
a limited number of sonographers conducting assessments, thus
reducing inter-observer bias. Limitations of our data include that
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women recruited to the study were not an unselected group
of women, but rather young women seeking fertility treatment.
Consequently, women over 35 years, with low AMH < 10
pmol/L, or obesity, were not included in the present study.
Furthermore, it was not possible to address whether higher values
of AMH over the reporting limit of the assay would confer even
greater risk of menstrual disturbance. Thus, further prospective
research in an unselected population with newer automated
assays is indicated to determine whether the value of an AMH
level in predicting menstrual disturbance is underestimated in
the current study (11).
In conclusion, our data suggests that AMH is a strong
predictor for menstrual disturbance due to PCOS and that the
risk of menstrual disturbance was increased with the degree
of elevation of AMH. AMH performed better than AFC in
predicting menstrual disturbance, although the combination
of both parameters outperformed AMH alone. Furthermore,
women with a greater number of features of PCOS had higher
AMH levels than those with fewer features, suggesting that AMH
could reflect the certainty of diagnosis. Our data suggests that
AMH is a promising marker for the identification of menstrual
disturbance due to PCOS.
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Supplementary Figure 1 | (A) Scattergram (median ± IQR) of serum AMH
(pmol/L) in women by the number of features of PCOS (new PCOS criteria).
Groups were compared by the Kruskal Wallis test with post-hoc Dunn’s multiple
comparison test. Serum AMH was increased by the number of features of PCOS.
∗∗∗∗P < 0.0001. (B) Scattergram (median ± IQR) of AFC in women by the number
of features of PCOS (new PCOS criteria). Groups were compared by Kruskal
Wallis test with post-hoc Dunn’s multiple comparison test. AFC was increased by
the number of features of PCOS. ∗P < 0.05, ∗∗∗∗P < 0.0001. (C) Scattergram
(median ± IQR) of FAI in women by the number of features of PCOS (new PCOS
criteria). Groups were compared by the Kruskal Wallis test with post-hoc Dunn’s
multiple comparison test. FAI was increased by the number of features of PCOS.
∗P < 0.05, ∗∗P < 0.01. (D) Scattergram (median ± IQR) of BMI (kg/m2) in women
by number of features of PCOS based on new criteria. Groups were compared by
the Kruskal Wallis test with post-hoc Dunn’s multiple comparisons test. Women
with average menstrual cycle length of ≥35 days have higher AMH levels
compared to those with menstrual cycle length of ≤27 days (P < 0.0001) or those
with menstrual cycle length of 28–30 days. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Supplementary Figure 2 | (A) Scattergram (median ± IQR) of serum AMH
(pmol/L) by sonographic morphology of each ovary as either Normal (Norm),
Multicystic (MCO), or Polycystic (PCO). The sample size in each group was as
follows: Norm Norm (n = 26); Norm MCO (n = 9); MCO MCO (n = 18); MCO PCO
(n = 5); Norm PCO (n = 10); PCO PCO (n = 119). There were no significant
differences between groups. (B) Scattergram (median ± IQR) of AFC by
sonographic morphology of ovaries. Comparison was made by the Kruskal Wallis
test with Tukey’s multiple comparison test. Women with bilateral PCO morphology
had higher AFC than those with bilateral Normal morphology (P = 0.016) or
bilateral MCO morphology (P < 0.0001). ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001. (C)
Scattergram (median ± IQR) of Free Androgen Index (FAI) by sonographic
morphology of ovaries. (D) Frequency of oligomenorrhea was increased in women
with polycystic ovarian morphology (PCO) by univariate logistic regression (P <
0.001). The odds of oligomenorrhea was increased by 1.5-fold (95% CI
0.19–11.8) in women with bilateral multicystic ovarian morphology (MCO-MCO)
and 10.7-fold (95% CI 2.4–47.1) in women with bilateral polycystic ovarian
(PCO-PCO) morphology in comparison to those with normal ovarian morphology.
Supplementary Figure 3 | (A) Total Antral Follicle Count (AFC) was associated
with Total Ovarian Volume (ml) (sum of left and right ovarian volumes; r2 = 0.25, P
< 0.0001). (B) Scattergram (median ± IQR) of the volume of each ovary (mls) by
its morphology: either normal, multicystic (MCO), or polycystic (PCO). Groups
were compared by the Kruskal-Wallis test with post-hoc Dunn’s multiple
comparison test. Ovarian volume was greater in PCO morphology ovaries than
normal morphology ovaries. ∗∗∗∗P < 0.0001. (C) Scattergram (median ± IQR) of
ovarian volume per antral follicle (mls) (ovarian volume divided by antral follicle
count in each ovary) by categories of morphology of that ovary. Groups were
compared by the Kruskal-Wallis test with post-hoc Dunn’s multiple comparison
test. Ovarian volume per antral follicle was lower in PCO ovaries than normal
morphology ovaries. ∗∗∗∗P < 0.0001. (D) Scattergram (median ± IQR) of ovarian
volume per antral follicle (mls) (i.e., total ovarian volume divided by total antral
follicle count from both ovaries) by categories of ovarian morphology. Groups were
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compared by Kruskal-Wallis with post-hoc Dunn’s multiple comparison test.
Ovarian volume per antral follicle was reduced in women with bilateral PCO
morphology in comparison to those with bilateral normal ovarian morphology. ∗P
< 0.05, ∗∗∗∗P < 0.0001. (E) Bar graph (mean ± SD) of ovarian volume per antral
follicle (mls) by categories of serum AMH (pmol/L). Groups were compared by the
Kruskal-Wallis with post-hoc Dunn’s multiple comparison test. Ovarian volume per
antral follicle was lower in women with higher serum AMH. ∗P < 0.05, ∗∗P < 0.01.
(F) Frequency of oligomenorrhea decreased with increased category of ovarian
volume per antral follicle (mls). Groups were compared by univariate logistic
regression. The odds of oligo/amenorrhea was reduced in women with increased
ovarian volume per antral follicle when compared with those with ovarian volume
per antral follicle 0–0.25; ovarian volume per antral follicle 0.26–0.50; OR 0.15
(95% CI 0.04–0.60), 0.51–0.75; OR 0.13 (95% CI 0.03–0.56), 0.76–1.00; OR 0.10
(95% CI 0.02–0.54), >1.00; OR 0.03 (95% CI 0.01–0.34).
Supplementary Table 1 | Median and interquartile range (IQR) of serum
anti-Mullerian hormone (AMH) and of total antral follicle count (AFC) are presented.
Five women were not included in this analysis due to missing data. Serum AMH
and total antral follicle counts (AFC) in eumenorrheic and oligo/amenorrheic
women were compared by the Mann-Whitney U test.
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